Solid Tumor Antigens

Cat. No.

A25179

CAS No.

2378046-35-4

Zaptuzumab

Synonyms: AD5-10

Zaptuzumab is a humanized monoclonal antibody targeting DR5 with high specificity and affinity. This compound effectively induces apoptosis in cancer cells through caspase activation and autophagic cell death, while also promoting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, Zaptuzumab disrupts redox homeostasis by generating reactive oxygen species (ROS) and decreasing glutathione levels. It has demonstrated significant tumor growth suppression and favorable safety profiles in various xenograft mouse models, making it a valuable tool in cancer research.

Cat. No.

A44223

CAS No.

1612758-88-9

Tabituximab barzuxetan (exclude Y90)

Synonyms: OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01

Tabituximab barzuxetan is a radioimmunoconjugate that combines a humanized monoclonal antibody with a targeting moiety directed against FZD-10. This compound exhibits significant anti-tumor activity and is particularly relevant for research involving synovial sarcoma. Its unique mechanism allows for targeted therapeutic applications, making it a valuable tool for cancer research.

Cat. No.

A53626

CAS No.

2650574-80-2

Turmetabart

Synonyms: Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody

Turmetabart is a humanized IgG1 monoclonal antibody targeting SEZ6, a cell surface protein involved in various cellular signaling pathways. This antibody is suitable for synthesizing antibody-drug conjugates (ADCs), including the compound ABBV-011, facilitating targeted delivery of therapeutic agents. The antibody is also applicable in research exploring the role of SEZ6 in cancer biology and other disease processes.

Cat. No.

A54677

CAS No.

3037073-85-8

Onvontatug

Synonyms: BAT8006 Antibody

Onvontatug is a humanized monoclonal antibody designed to target folate receptor α (FRα). This compound has demonstrated potential in constructing antibody-drug conjugates (ADCs) for therapeutic applications. It is particularly relevant for research involving platinum-resistant ovarian cancer, facilitating investigations into novel treatment modalities.

Cat. No.

A54678

CAS No.

3035565-36-4

Lazatatug

Lazatatug is a humanized IgEκ antibody targeting the folate receptor 1 (FOLR1). It exhibits significant antineoplastic activity by binding to FOLR1, which is often overexpressed in various tumors. This antibody is primarily utilized in cancer research to investigate mechanisms of tumor growth and to explore potential therapeutic applications in FOLR1-positive malignancies.

Cat. No.

A57302

CAS No.

3038456-02-6

Zarutatug

Synonyms: TORL-3-600 antibody

Zarutatug is a humanized IgG1κ antibody that targets cadherin 17 (CDH17), exhibiting antineoplastic activity. This antibody is designed for research applications related to cancer biology, specifically in studies involving CDH17 and its role in tumor progression. Zarutatug provides a valuable tool for investigating therapeutic strategies in malignancies where CDH17 is implicated.

Cat. No.

A57319

CAS No.

3004869-54-6

Gaspantatug

Gaspantatug is a humanized IgG1κ antibody specifically designed to target CLDN18.2, a critical marker associated with certain malignancies. This antibody demonstrates robust biological activity in modulating immune responses against CLDN18.2-expressing tumors. It is intended for use in cancer research and therapeutic applications related to solid tumors.

Cat. No.

A57321

CAS No.

3038456-00-4

Elatatug

Synonyms: TORL-2-307 antibody

Elatatug is a humanized IgG1κ antibody targeting claudin 18 (CLDN18), exhibiting antineoplastic activity. This antibody is designed for use in cancer research, particularly in studies related to tumors expressing CLDN18. Elatatug may facilitate the exploration of novel therapeutic strategies for CLDN18-positive malignancies. An appropriate isotype control is Human IgG1 kappa, Isotype Control.

Cat. No.

A65058

CAS No.

3036556-50-7

Notiretatug

Synonyms: SHR-A2102 antibody

Notiretatug is a humanized IgG1κ antibody that specifically targets Nectin-4, a cell adhesion molecule implicated in various cancers. This antibody demonstrates significant potential in cancer research, particularly in studies focused on tumor microenvironments and immune responses. It serves as a valuable tool for exploring Nectin-4's role in tumor progression and therapeutic interventions.

Cat. No.

A65670

CAS No.

213327-37-8

Oregovomab

Synonyms: Alt-2 monoclonal antibody; MAB-B43.13; Oregovamab

Oregovomab is a murine monoclonal antibody that specifically targets CA125, a glycoprotein often overexpressed in ovarian cancer cells. This antibody is engineered to stimulate a cytotoxic immune response against tumor cells that express CA125, making it a valuable tool for cancer immunotherapy research. Oregovomab is widely used in studies investigating the therapeutic potential of targeted immune responses in ovarian and other CA125-related malignancies.

Cat. No.

A79153

CAS No.

3038456-05-9

Roltotatug

Synonyms: TORL-4-500 antibody

Roltotatug is a humanized IgG1κ antibody that specifically targets the dipeptidyl peptidase-like protein 6 (DLK1). This antibody has been utilized in various biological studies to elucidate the role of DLK1 in cellular processes and disease mechanisms. Applications include research in developmental biology, neurobiology, and potential therapeutic interventions involving DLK1 modulation.

Cat. No.

AT0015

CAS No.

916138-87-9

Girentuximab

Synonyms: G250; cG250

Girentuximab (G250) is a chimeric IgG1 monoclonal antibody that selectively binds carbonic anhydrase IX (CAIX), a transmembrane glycoprotein highly expressed in clear cell renal cell carcinoma (ccRCC) and hypoxic tumor environments. It is widely used in tumor imaging, targeted therapy development, and CAIX-related cancer biology studies.

Cat. No.

AT0022

CAS No.

792921-10-9

Abagovomab

Synonyms: Anti-Human CA-125 Recombinant Antibody

Abagovomab is a murine anti-idiotypic monoclonal antibody that mimics the tumor-associated antigen CA-125. Generated from mouse hybridoma technology, it is capable of eliciting both humoral and cellular immune responses. Abagovomab is used in ovarian cancer research, particularly in studies of immunotherapy and tumor antigen mimicry.

Cat. No.

AT0030

CAS No.

892553-42-3

Etaracizumab

Synonyms: LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody

Etaracizumab is a human IgG1 monoclonal antibody that targets the integrin αvβ3, which plays a critical role in angiogenesis, tumor invasion, and metastasis. By inhibiting αvβ3-mediated cell adhesion and migration, Etaracizumab is used in research on cancer biology, anti-angiogenic therapies, and metastatic melanoma.

Cat. No.

AT0039

CAS No.

2938864-87-8

Tizetatug

Tizetatug is a bispecific IgG1κ monoclonal antibody targeting TACSTD2 (TROP2), a transmembrane glycoprotein commonly overexpressed in epithelial cancers. Tizetatug is designed for dual antigen engagement and is suited for use in studies of TROP2-directed cancer therapy and antibody-based tumor targeting. Recommended isotype control: Human IgG1 kappa isotype control.

Cat. No.

AT0050

CAS No.

1204740-23-7

Cantuzumab

Cantuzumab is a monoclonal antibody that binds to CanAg, a tumor-associated antigen overexpressed in many epithelial cancers. It is commonly used as the targeting component of antibody-drug conjugates (ADCs), including Cantuzumab mertansine and Cantuzumab ravtansine, for research on targeted cytotoxic delivery and cancer therapy.

Cat. No.

AT0058

Anti-B7-H6/NCR3LG1 Antibody

Cat. No.

AT0072

CAS No.

1365267-33-9

Codrituzumab

Synonyms: GC33; RO5137382

Codrituzumab (GC33) is a humanized monoclonal antibody that selectively targets glypican-3 (GPC3), a cell surface oncofetal protein predominantly expressed in hepatocellular carcinoma (HCC). This antibody demonstrates a high affinity for GPC3, with a dissociation constant (Kd) of 0.673 nM, indicating strong and specific binding. Codrituzumab functions by inducing antibody-dependent cellular cytotoxicity (ADCC), leading to the inhibition of tumor growth in affected cellular models. This makes it a valuable tool for research focused on cancer biology, particularly in studies investigating the mechanisms of immune response in liver cancer.

Cat. No.

AT0091

Anti-TROP-2 Antibody (Pr1E11)

The Anti-TROP-2 Antibody (Pr1E11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human TROP-2. For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody is ideal for research applications requiring precise TROP-2 targeting.

Cat. No.

AT0099

Anti-CEACAM1/CD66a Antibody

The Anti-CEACAM1/CD66a Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CEACAM1/CD66a antigen. This antibody features the human IgG1 heavy chain and human kappa light chain, with an estimated molecular weight of 144.98 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications requiring precise targeting of the CEACAM1/CD66a protein.

Cat. No.

AT0122

CAS No.

1363687-32-4

Dinutuximab

Synonyms: APN-311

Dinutuximab (Unituxin; APN-311) is a chimeric monoclonal antibody derived from both human and murine sources, specifically targeting GD2. This antibody has demonstrated significant efficacy in prolonging event-free and overall survival in patients with high-risk neuroblastoma. It is used in a therapeutic regimen that includes granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]), enhancing its effectiveness in clinical applications.

Cat. No.

AT0127

Anti-TM4SF1 Antibody

Synonyms: AGX101 antibody

The Anti-TM4SF1 Antibody is a human monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target the TM4SF1 protein. This antibody features a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control, researchers should use the Human IgG1 kappa, Isotype Control, ensuring accurate and reliable experimental comparisons. This product is essential for studies focused on the biological functions and pathological roles of TM4SF1 in cellular processes.

Cat. No.

AT0133

CAS No.

2058047-65-5

Murlentamab

Synonyms: 3C23K; GM102

Murlentamab (3C23K; GM102) is a humanized monoclonal antibody targeting AMHRII, the anti-Müllerian hormone receptor II. This antibody plays a crucial role in enhancing macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), a key mechanism in immune defense against tumors. Murlentamab facilitates the creation of a pro-inflammatory and anti-tumor microenvironment, effectively recruiting and activating T cells. Additionally, it inhibits tumor growth by directing the differentiation of naïve macrophages and reprogramming tumor-associated macrophages (TAMs) towards phenotypes that support tumor eradication. This makes Murlentamab a valuable tool for research in cancer immunotherapy and macrophage biology.

Cat. No.

AT0157

CAS No.

3009829-91-5

Laventatug

Laventatug is a humanized monoclonal antibody that specifically targets the human SLC39A6 protein. By binding to SLC39A6, Laventatug disrupts the intracellular transport of zinc ions, a process integral to tumor cell viability and proliferation. This interference with zinc ion homeostasis confers Laventatug with potent antitumor properties, making it an invaluable tool for cancer research, particularly in studies exploring the molecular mechanisms of tumor growth and progression.

Cat. No.

AT0161

CAS No.

648904-28-3

Bavituximab

Synonyms: Anti-Human Phosphatidylserine Recombinant Antibody

Bavituximab is a recombinant monoclonal antibody that targets phosphatidylserine (PS), a key component of the tumor microenvironment. This antibody functions by suppressing tumor growth through dual mechanisms: direct targeting of tumor vasculature and reactivation of antitumor immune responses. In combination with chemotherapeutic agents Paclitaxel and Carboplatin, Bavituximab has demonstrated enhanced inhibitory effects on non-small-cell lung cancer, suggesting its potential utility in oncology research and therapeutic applications.